4D Molecular Therapeutics Achieves 11-Month Enrollment of 500+ Patients in Phase 3 Wet AMD Trial
4D Molecular Therapeutics completed enrollment for its 4FRONT-1 Phase 3 trial of 4D-150 in wet AMD within 11 months, over-enrolling more than 500 randomized patients. Company expects topline 4FRONT-1 data in H1 2027 and 4FRONT-2 enrollment to complete by H2 2026 with topline data in H2 2027.
1. Enrollment Milestone Achieved
4D Molecular Therapeutics finalized patient recruitment for its 4FRONT-1 Phase 3 trial of 4D-150 in wet age-related macular degeneration within 11 months, surpassing the planned 500-patient target. This over-enrollment reflects strong investigator and patient enthusiasm and enhances the statistical robustness of the trial.
2. Phase 3 Program Timeline
Topline efficacy and safety results from 4FRONT-1 are scheduled for release in the first half of 2027. Meanwhile, global site activation for the second registrational trial, 4FRONT-2, remains on track to complete enrollment by the second half of 2026, with topline data expected in H2 2027.